A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose
HIV Infections
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring Vaccines, Synthetic, Vaccinia Virus, Viral Vaccines, HIV-1, HIV Envelope Protein gp160, AIDS Vaccines, HIV Seronegativity, HIV Preventive Vaccine
Eligibility Criteria
Inclusion Criteria Patients must be: Normal, healthy, HIV-negative adults who fully comprehend the purpose and details of the study. Available for 2 years of follow-up. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: History of positive PPD (tuberculin test) and abnormal chest x-ray. Positive syphilis serology (e.g., RPR). Positive for circulating hepatitis B surface antigen. Patients with the following are excluded: They or their sexual partners have identifiable high-risk behavior for HIV infection. History of immunodeficiency or chronic illness. Evidence of psychological or psychiatric problems that may lead to noncompliance. Prior Medication: Excluded: Immunosuppressive medications. Prior Treatment: Excluded: Blood transfusions or cryoprecipitates within the past 6 months.
Sites / Locations
- St. Louis Univ. School of Medicine AVEG
- Univ. of Rochester AVEG
- Vanderbilt Univ. Hosp. AVEG